Our scientific successes are intended to help improve people’s lives. 1 Total Elanco revenue includes revenue from strategic exits. Combined 2018 full-year revenues for Elanco and Bayer Animal Health include revenues for products that may be divested in connection with the acquisition, including both Osurnia & Capstar. Elanco is well positioned in the attractive animal health industry, including enhanced scale, capabilities, and commercial leadership through the Bayer Animal Health acquisition. Bayer AG will receive $5.32 billion in cash, subject to customary purchase price adjustments, and $2.28 billion or approximately 68 million Elanco Animal Health common shares. Bayer’s eager to let Elanco take animal health off its hands so it can focus its healthcare efforts squarely on pharmaceuticals. After Bloomberg reported August 7 that a deal to merge Elanco and the animal-health unit of Bayer (BAYN) was imminent, Elanco stock fell nearly 10% in a matter of days. 2 animal health company behind Zoetis Inc. with its $7.6 billion acquisition of Bayer AG's animal health business. At a Glance; Health Care; Nutrition; Our Scientists; Open Innovation; Social Innovation; Employee Innovation; Products. Elanco Animal Health is one of the largest companies in its field and it plans to get a lot bigger with the $7.6 billion acquisition of Bayer’s animal-health business. The request was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the review continues to progress as expected. 73 million Elanco shares. Bloomberg reported August 7 that Elanco (ticker: ELAN) was expected to announce a deal Tuesday to merge with an animal health unit of the German health care giant Bayer AG (BAYN). A newly added research report by Orbis Pharma Reports evaluating various developments and eventful milestones in global Coccidiostat market … Q3'18. Better Harvests and Healthy Families; Leaps by Bayer; Research and Development. As part of the transaction with Bayer A.G., $35 million was reflected in the purchase price attributable to Elanco’s restructuring costs. Cash severance payments will be distributed over the next two years. A big seller for Bayer is its Advantage platform, which includes flea and tick medicine. Q3'19. - Elanco Animal Health has agreed to make changes to a US$7.6-billion deal to buy several health care products for animals from Bayer AG … Elanco : Bayer Animal Health Business(A) Pro forma Adjustments : Note : Pro forma : ASSETS ... the reclassification of balances to align Bayer Animal Health Business’ financial statement presentation with the Elanco presentation. This base is materially correct based on the public filings of Bayer and Elanco; however, due to certain data limitations, including foreign exchange rates, these numbers may have some non-material differences to actual results. Elanco Animal Health Inc. will become the No. Strengthened and expanded Innovation, Portfolio, Productivity strategy to deliver long-term growth algorithm targeting ~3%-4% average annual revenue growth, double-digit annual adjusted EBITDA... | December 15, 2020 This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor.Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. This base is a Through extensive collaboration between Bayer, Elanco, and TCS, we … $3.2 $2.5 $2.6 $2.6 $1.9 $0.6 $2.6 $2.2 $2.1 $1.6 $1.1 $1.1 $5.8 $4.7 $4.7 $4.2 $3.11 $1.7 Explorer Bayer is an innovation company with a more than 150-year history. EBITDA Margin. The legacy Elanco business saw … Sales . 4,163. Elanco Animal Health Incorporated has received a second request for information from the U.S. Federal Trade Commission (FTC) concerning its previously announced acquisition of Bayer AG’s animal health business.. Elanco Animal Health Hosts Investor Day, Demonstrating Inflection Point Toward Accelerated Value Creation Business Wire Dec 15, 2020 08:00 AM EST Strengthened and expanded Innovation, Portfolio, Productivity (IPP) strategy to deliver long-term growth algorithm targeting ~3%-4% average annual revenue growth, double-digit annual adjusted EBITDA growth, and double-digit annual … Elanco … In million €, ∆% yoy, before special items. 1,554. Elanco is well positioned on all fronts and we believe will be even stronger with the addition of Bayer Animal Health. Evercore analyst Umer Raffat said investors are rattled by the deal, citing Bayer Animal Health's heavy reliance on a few key products and potential antitrust issues stemming from the combined company's portfolio overlap. This base is materially correct based on the public filings of Bayer and Elanco; however, due to certain data limitations, including foreign exchange rates, these numbers may have some non-material differences to actual results. Overview ; News on Innovation. See Appendix to this presentation for more information, including GAAP to non GAAP reconciliations. 11.3%. EBITDA . Overall, third-quarter revenue grew by 16% to $889 million, helped by a $196 million contribution from the legacy Bayer business. 4,504. Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. Coccidiostat Market 2020 Overview, Analysis,Growth Opportunities and Forecast to 2026 : Zoetis, Ceva, Elanco, Bayer Healthcare Animal Healthcare, Huvepharma, Merck Animal Healthcare, Rabar Animal Nutrition, Vitafor. 1,527. b. A big plus from the Bayer deal: It increases Elanco’s exposure to pet products to 48% of sales from 38%. 73 million Elanco shares. GATINEAU, Que. Elanco expects to incur a restructuring charge of $130 million to $145 million in Q3 2020 along with $40 million to $45 million in Q4 2020. On August 20, 2019, Elanco will host an investor presentation regarding the Purchase Agreement and the Transaction. Products. Additionally, Raffat said investors believe the deal distracts Elanco from its independent margin expansion goals — despite the company's assertion that the acquisition strengthens and accelerates its strategy. Q3'18. Elanco is providing a 2020 pro forma reference base, inclusive of fourth quarter of 2020 guidance. 73 million Elanco shares. Very few of Elanco's and Bayer's products still have patent protection, while in Bayer's portfolio, only Advantage Multi still has protection through October 2020. In million €, ∆% yoy, Fx & portfolio adj. 10 months ago. December 15, 2020 anita. This represents a 70 percent to 30 percent cash-to-equity mix. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor. 12.1.4 Bayer Animal Growth Enhancers Products Offered 12.1.5 Bayer Recent Development 12.2 Elanco 12.2.1 Elanco Corporation Information 12.2.2 Elanco Business Overview 12.2.3 Elanco Animal Growth Enhancers Sales, Revenue and Gross Margin (2015-2020) 12.2.4 Elanco Animal Growth Enhancers Products Offered 12.2.5 Elanco Recent Development 12.3 Zoetis Q3'19. WSJ: Investors Don’t Love Elanco’s New Tricks JPMorgan: Initial Thoughts on Bayer Animal Health UBS: Highlights So Far on ELAN / Bayer Deal DEAL PROFILE OVERVIEW HIGHLIGHTS Elanco, the animal health unit spun out of Eli Lilly in 2018, announced its acquisition of Bayer’spet and livestock medications business for $7.6 billion. 13.3%. A lot has happened at Elanco (NYSE:ELAN) over the last few years. Introduction. Bayer Roadshow Presentation | November 2019. This means that the number of Elanco shares that Bayer receives increases (decreases) in the event of share price decreases (increases) within this 7.5% corridor.Based on the closing price of Elanco shares on September 30, 2019, Bayer would receive approx. On August 20, 2019, Elanco issued a press release announcing that Elanco had entered into the Purchase Agreement with Bayer. before special items . "Bayer's performance brings momentum into the close and we look forward to welcoming our new colleagues to the Elanco team. Elanco will finance the transaction through both cash and equity.